Research
RBC Capital Markets Cuts Oxford Biomedica PT, Affirms at Outperform
RBC Capital Markets on Monday reduced the price target for cell and gene therapy company Oxford Biomedica (OXB.L) to 9 pounds sterling from 11.40 pounds, while keeping its outperform rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
$OXB.L
